Prostatitis Explained Prostatitis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Departmentof UROLOGY
DEPARTMENT of UROLOGY UPDATE New Treatments for Benign Prostatic Hyperplasia Expanded Choices Provide Relief for a Common Condition FALL 2008 Vol.19 | No.2 The symptoms of an enlarged prostate include a weak stream, trouble starting and gland, called benign prostatic hyper- stopping, the frequent feeling of needing to Clinical Update p. 4 plasia (BPH), are familiar to a substantial urinate, and the sense that the bladder isn’t Kidney Cancer Vaccine p. 5 proportion of men older than 50. empty after urination. About half of men in their 50s and 80-90 percent Erectile Dysfunction Research p. 5 “To some degree, BPH affects all men as they of those older than 80 have enlarged prostates, age,” says Allan Pantuck, MD, MS, associate Clinical Trials p. 6 caused by changes in hormone balance and cell professor and physician in the UCLA Integrative growth. As their prostate begins to squeeze or Profile: Oscar Rivera, LVN p. 8 Urology Program, which combines the best partially block the surrounding urethra — the of preventative approaches, medical counseling, Kudos p. 9 tube that carries the urine from the bladder out nutritional science, and complementary medical of the body — many of these men experience Donor Notes p. 9 approaches for patients interested in the bothersome urinary symptoms, which can prevention and treatment of urologic conditions. Profile: Arthur Schapiro p. 9 “The prostate forms a channel that the urine passes through as it comes out of the bladder. As the prostate enlarges, there is increased resistance to the bladder’s ability to empty. This tends to also lead to changes in the bladder, including a decreased ability to hold urine.” BPH can wreak havoc with quality of life — in addition to the discomfort, some men are forced to get up several times during the night. -
GERONTOLOGICAL NURSE PRACTITIONER Review and Resource M Anual
13 Male Reproductive System Disorders Vaunette Fay, PhD, RN, FNP-BC, GNP-BC GERIATRIC APPRoACH Normal Changes of Aging Male Reproductive System • Decreased testosterone level leads to increased estrogen-to-androgen ratio • Testicular atrophy • Decreased sperm motility; fertility reduced but extant • Increased incidence of gynecomastia Sexual function • Slowed arousal—increased time to achieve erection • Erection less firm, shorter lasting • Delayed ejaculation and decreased forcefulness at ejaculation • Longer interval to achieving subsequent erection Prostate • By fourth decade of life, stromal fibrous elements and glandular tissue hypertrophy, stimulated by dihydrotestosterone (DHT, the active androgen within the prostate); hyperplastic nodules enlarge in size, ultimately leading to urethral obstruction 398 GERONTOLOGICAL NURSE PRACTITIONER Review and Resource M anual Clinical Implications History • Many men are overly sensitive about complaints of the male genitourinary system; men are often not inclined to initiate discussion, seek help; important to take active role in screening with an approach that is open, trustworthy, and nonjudgmental • Sexual function remains important to many men, even at ages over 80 • Lack of an available partner, poor health, erectile dysfunction, medication adverse effects, and lack of desire are the main reasons men do not continue to have sex • Acute and chronic alcohol use can lead to impotence in men • Nocturia is reported in 66% of patients over 65 – Due to impaired ability to concentrate urine, reduced -
The Fine Art of Prostate Massage
The Fine Art of Prostate Massage Part I: What exactly are we dealing with here? Or, Anatomy, 101 • What is the prostate gland? Very simply, it is the part of the male body that store and secretes an essential part of semen. More specifically, the prostate gland produces an alkaline fluid that makes up about 30% of the semen. The alkalinity, interestingly, helps offset female vaginal acidity. • Where is the prostate gland? The prostate is located in lower abdominal area, roughly between the bladder and the rectal wall (which makes it easy to feel and to play with). Notice that one part of the prostate (shown in green) runs along the wall near the rectal area. This is the part that we are interested in. The prostate is slightly larger than a walnut, which can make both exams and play a bit challenging. Anatomy is highly variable, which means we have to be patient. • Do biological females have a prostate gland? Not in the same way that a biological male does. There is a small gland, also called the Skene’s Gland or the paraurethural gland. While it is homologous to the male prostate, it serves a slightly different purpose. An authoritative medical group officially called the female prostate such in 2002, and it is thus “officially” known as a prostate. It does play an active role during the female orgasm. The female prostate is located in approximately the same place as the male prostate. The anatomy here, though, is also highly variable. It may play a significant part in female “ejaculation”. -
Chronic Bacterial Prostatitis Treated with Phage Therapy After Multiple Failed Antibiotic Treatments
CASE REPORT published: 10 June 2021 doi: 10.3389/fphar.2021.692614 Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments Apurva Virmani Johri 1*, Pranav Johri 1, Naomi Hoyle 2, Levan Pipia 2, Lia Nadareishvili 2 and Dea Nizharadze 2 1Vitalis Phage Therapy, New Delhi, India, 2Eliava Phage Therapy Center, Tbilisi, Georgia Background: Chronic Bacterial Prostatitis (CBP) is an inflammatory condition caused by a persistent bacterial infection of the prostate gland and its surrounding areas in the male pelvic region. It is most common in men under 50 years of age. It is a long-lasting and Edited by: ’ Mayank Gangwar, debilitating condition that severely deteriorates the patient s quality of life. Anatomical Banaras Hindu University, India limitations and antimicrobial resistance limit the effectiveness of antibiotic treatment of Reviewed by: CBP. Bacteriophage therapy is proposed as a promising alternative treatment of CBP and Gianpaolo Perletti, related infections. Bacteriophage therapy is the use of lytic bacterial viruses to treat University of Insubria, Italy Sandeep Kaur, bacterial infections. Many cases of CBP are complicated by infections caused by both Mehr Chand Mahajan DAV College for nosocomial and community acquired multidrug resistant bacteria. Frequently encountered Women Chandigarh, India Tamta Tkhilaishvili, strains include Vancomycin resistant Enterococci, Extended Spectrum Beta Lactam German Heart Center Berlin, Germany resistant Escherichia coli, other gram-positive organisms such as Staphylococcus and Pooria Gill, Streptococcus, Enterobacteriaceae such as Klebsiella and Proteus, and Pseudomonas Mazandaran University of Medical Sciences, Iran aeruginosa, among others. *Correspondence: Case Presentation: We present a patient with the typical manifestations of CBP. -
2002 Asa Program.Pdf
schedule at a lance Wednesday, April 24, 2002 • Genetics and Biology of Adult Male Germ Cell 8:00 am Andrology Laboratory Workshop Tumors The Andrology Laboratory of the Future: Raju S.K. Chaganti, Memoria l Sloan-Kettering Impact of the Genomic and Proteomic • Modeling Human Disease Through Transgenesis Revolutions (concludes at 5:00 pm) Sarah Comerford, UTSWMS & HHI • How to Find Cellular Proteins that Sense the 5:30 pm Welcome and Opening Remarks Environment Da vid Garbers, HHM/ 5:45 pm Distinguished Andrologist Award 6:00 pm Serano Lecture 12:00 pm Laboratory Science Lunch • Of Genes and Genomes 1:30 pm Symposium Ill: Do Gene Defects Impact Da vid Botstein, Stanford University Male Reproduction: If So, How? •The Battle of the Sexes: Sry and the Control of Testis 7:15 pm Welcome Reception Organogenesis Blanche Capel, Duke Univ. Med. Ctr. Thursday, April 25, 2002 • Natural Potent Androgens: Lessons from Human Genetic Models 8:00 am Solvay/Unimed Lecture J. /mperato-McGinley, Cornell University •Androgen Therapy in the Older Man-Where • Genetic Defects in Male Reproduction Are We Now and Where Are We Going? Stephanie Seminara, Harvard University Lisa Te nover, Emory University 3:00 pm Refreshment Break and Exhibits 8:55 am Distinguished Service Award 3:15 pm Plenary Lecture 9:05 am Biopore Lecture • The Ins & Outs of PSMA, the Evolving and • Global Analysis of Germline Gene Expression Intriguing Tale of its Prostate Biology & Tumor Sam Wa rd, University of Arizona Targeting WO. Heston, Cleveland Clinic 10:00 am Coffee Break and Exhibits 4:05 pm Schering Lecture 10:30 am Concurrent Oral Sessions I, II, Ill • Bioethics and Stem Cell Research • Basic and Clinical Aspects of Male Sexual Laurie Zoloff, San Fra ncisco State Univ. -
Andrological Sciences Official Journal of the Italian Society of Andrology
Vol. 17 • No. 2 • June 2010 Journal of ANDROLOGICAL SCIENCES Official Journal of the Italian Society of Andrology Cited in Past Editors Editorial Board Fabrizio Menchini Fabris (Pisa) Antonio Aversa (Roma) SCOPUS Elsevier Database 1994-2004 Ciro Basile Fasolo (Pisa) Carlo Bettocchi (Bari) Edoardo Pescatori (Modena) Guglielmo Bonanni (Padova) Paolo Turchi (Pisa) Massimo Capone (Gorizia) 2005-2008 Tommasi Cai (Firenze) Luca Carmignani (Milano) Antonio Casarico (Genova) Editors-in-Chief Carlo Ceruti (Torino) Vincenzo Ficarra (Padova) Fulvio Colombo (Milano) Andrea Salonia (Milano) Luigi Cormio (Foggia) Federico Dehò (Milano) Giorgio Franco (Roma) Editor Assistant Andrea Galosi (Ancona) Ferdinando Fusco (Napoli) Giulio Garaffa (London) Andrea Garolla (Padova) Paolo Gontero (Torino) Managing Editor Vincenzo Gulino (Roma) Vincenzo Gentile (Roma) Massimo Iafrate (Padova) Copyright Sandro La Vignera (Catamia) SIAS S.r.l. • via Luigi Bellotti Bon, 10 Francesco Lanzafame (Catania) 00197 Roma Delegate of Executive Committee Giovanni Liguori (Trieste) of SIA Mario Mancini (Milano) Editorial Office Giuseppe La Pera (Roma) Alessandro Mofferdin (Modena) Lucia Castelli (Editorial Assistant) Nicola Mondaini (Firenze) Tel. 050 3130224 • Fax 050 3130300 Giacomo Novara (Padova) [email protected] Section Editor – Psychology Enzo Palminteri (Arezzo) Pacini Editore S.p.A. • Via A. Gherardesca 1 Annamaria Abbona (Torino) Furio Pirozzi Farina (Sassari) 56121 Ospedaletto (Pisa), Italy Giorgio Pomara (Pisa) Marco Rossato (Padova) Publisher Statistical Consultant Paolo Rossi (Pisa) Pacini Editore S.p.A. Elena Ricci (Milano) Antonino Saccà (Milano) Via A. Gherardesca 1, Gianfranco Savoca (Palermo) 56121 Ospedaletto (Pisa), Italy Omidreza Sedigh (Torino) Tel. 050 313011 • Fax 050 3130300 Marcello Soli (Bologna) [email protected] Paolo Verze (Napoli) www.pacinimedicina.it Alessandro Zucchi (Perugia) www.andrologiaitaliana.it INDEX Journal of Andrological Sciences EDITORIAL PCA3 a promising urine biomarker for prostate cancer diagnosis V. -
Sexually Transmitted Infections Treatment Guidelines, 2021
Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized -
Reference ID: 4555351 See 17 for PATIENT COUNSELING INFORMATION and Medication Guide
HIGHLIGHTS OF PRESCRIBING INFORMATION 5 mg dapagliflozin/1000 mg metformin HCl extended-release (3) These highlights do not include all the information needed to use 10 mg dapagliflozin/500 mg metformin HCl extended-release (3) XIGDUO XR safely and effectively. See full prescribing information for 10 mg dapagliflozin/1000 mg metformin HCl extended-release (3) XIGDUO XR. ------------------------------ CONTRAINDICATIONS ----------------------------- ® XIGDUO XR (dapagliflozin and metformin HCl extended-release) Severe renal impairment: (eGFR below 30 mL/min/1.73 m2), end-stage tablets, for oral use renal disease or dialysis. (4, 5.1) Initial U.S. Approval: 2014 History of serious hypersensitivity to dapagliflozin or hypersensitivity to metformin HCl. (4, 6.1) WARNING: LACTIC ACIDOSIS Metabolic acidosis, including diabetic ketoacidosis. (4, 5.1) See full prescribing information for complete boxed warning. ----------------------- WARNINGS AND PRECAUTIONS ---------------------- Postmarketing cases of metformin-associated lactic acidosis have Lactic Acidosis: See boxed warning (2.3, 4, 5.1) resulted in death, hypothermia, hypotension, and resistant Hypotension: Before initiating XIGDUO XR, assess and correct volume bradyarrhythmias. Symptoms included malaise, myalgias, status in the elderly, patients with renal impairment or low systolic blood respiratory distress, somnolence, and abdominal pain. Laboratory pressure, and in patients on diuretics. Monitor for signs and symptoms abnormalities included elevated blood lactate levels, anion gap during therapy. (5.2, 6.1) acidosis, increased lactate/pyruvate ratio; and metformin plasma Ketoacidosis: Assess patients who present with signs and symptoms of levels generally >5 mcg/mL. (5.1) metabolic acidosis for ketoacidosis regardless of blood glucose level. If Risk factors include renal impairment, concomitant use of certain suspected, discontinue XIGDUO XR, evaluate and treat promptly. -
Specific Antigen Level and Serum Fasting Glucose, Total Cholesterol
Original Article DO I: 10.4274/uob.999 Bulletin of Urooncology 2018;17:59-62 Assessment of the Relationship Between Serum Prostate- Specific Antigen Level and Serum Fasting Glucose, Total Cholesterol and Neutrophil-Lymphocyte Ratio in Men Aged 50-70 Years with Prostate-Specific Antigen Level 0-10 ng/mL without Prostate Cancer Diagnosis Bora İrer MD İzmir Metropolitan Municipality Eşrefpaşa Hospital, Clinic of Urology, İzmir, Turkey Abstract Objective: To evaluate the relationship between serum prostate-specific antigen (PSA) level and total cholesterol, fasting blood glucose, and neutrophil- lymphocyte ratio (NLR) in men without prostate cancer. Materials and Methods: Between 2010 and 2017, 2631 male participants aged 50-70 years with a serum PSA level of 0-10 ng/mL were included from a population of 4643 healthy males who participated in a health screening program conducted by the İzmir Metropolitan Municipality Eşrefpaşa Hospital in the district villages of İzmir. Participants’ serum PSA, fasting blood glucose, total cholesterol levels, and NLR were retrospectively assessed. Participants were grouped as those with high and low serum PSA levels, high and low glucose levels, and high and low cholesterol levels. Differences between the groups in terms of serum PSA levels, serum total cholesterol, glucose, and NLR were analyzed. Results: The mean age of the participants was 60.2±5.4 years and the mean serum PSA level was 1.28±1.20 ng/mL. The mean PSA value was higher in the high cholesterol group (1.36±1.33 vs 1.19±1.02, p<0.001) compared to the low cholesterol group, and the mean PSA value in the high glucose group was lower than in the low glucose group (1.08±0.86 vs 1.32±1.25, p<0.001). -
A Systematic Review and Meta-Analysis Lei Zhang1*, Yi Wang1*, Zhiqiang Qin2*, Xian Gao3, Qianwei Xing4, Ran Li1, Wei Wang1, Ninghong Song1, Wei Zhang1
Journal of Cancer 2020, Vol. 11 177 Ivyspring International Publisher Journal of Cancer 2020; 11(1): 177-189. doi: 10.7150/jca.37235 Research Paper Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis Lei Zhang1*, Yi Wang1*, Zhiqiang Qin2*, Xian Gao3, Qianwei Xing4, Ran Li1, Wei Wang1, Ninghong Song1, Wei Zhang1 1. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210009, China. 2. Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. 3. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210009, China. 4. Department of Urology, The Affiliated Hospital of Nantong University, Nantong, 226001, China. *These authors contributed equally to this work. Corresponding authors: Wei Zhang, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, China. E-mail: [email protected], TEL: +08613901595401; Qianwei Xing, Department of Urology, The Affiliated Hospital of Nantong University, Nantong, 226001, China. E-mail: [email protected], TEL: +08615240552009. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.06.02; Accepted: 2019.09.27; Published: 2020.01.01 Abstract Background: No consensus has been reached on the definite associations among prostatitis, benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Hence, this meta-analysis was conducted to explore their triadic relation by summarizing epidemiological evidence. Methods: Systematical and comprehensive retrieval of online databases PubMed, PMC, EMBASE and Web of Science was performed to acquire eligible studies, up to April 1st, 2019. -
Narrative Review of Urinary Glycan Biomarkers in Prostate Cancer
1864 Review Article on Urinary Biomarkers of Urological Malignancies Narrative review of urinary glycan biomarkers in prostate cancer Shingo Hatakeyama1^, Tohru Yoneyama2^, Yuki Tobisawa3^, Hayato Yamamoto3, Chikara Ohyama1,2,3^ 1Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; 2Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; 3Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan Contributions: (I) Conception and design: S Hatakeyama; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Shingo Hatakeyama, MD. Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki 036- 8562, Japan. Email: [email protected]. Abstract: Prostate cancer (PC) is the second most common cancer in men worldwide. The application of the prostate-specific antigen (PSA) test has improved the diagnosis and treatment of PC. However, the PSA test has become associated with overdiagnosis and overtreatment. Therefore, there is an unmet need for novel diagnostic, prognostic, and predictive biomarkers of PC. Urinary glycoproteins and exosomes are a potential source of PC glycan biomarkers. Urinary glycan profiling can provide noninvasive monitoring of tumor heterogeneity and aggressiveness throughout a treatment course. However, urinary glycan profiling is not popular due to technical disadvantages, such as complicated structural analysis that requires specialized expertise. The technological development of glycan analysis is a rapidly advancing field. A lectin-based microarray can detect aberrant glycoproteins in urine, including PSA glycoforms and exosomes. -
Controversies in Using Urine Samples for Prostate Cancer Detection: PSA and PCA3 Expression Analysis
Clinical Urology Prostate Cancer detection International Braz J Urol Vol. 37 (6): 719-726, November - December, 2011 Controversies in using urine samples for Prostate Cancer detection: PSA and PCA3 expression analysis S. Fontenete, J. Silva, A.L. Teixeira, R. Ribeiro, E. Bastos, F. Pina, R. Medeiros Molecular Oncology Group and Virology LB (SF, JS, ALT, RR, RM), Portuguese Institute of Oncol- ogy of Porto; ICBAS, Abel Salazar Institute for the Biomedical Sciences (SF, JS, ALT, RR, RM), University of Porto; Research Department - Portuguese League Against Cancer (NRN) (JS, ALT, RR, RM), Porto; Centre of Genetics and Biotechnology (EB), University of Trás-os-Montes and Alto Douro; Department of Urology (FP), S. João Hospital, University of Porto Medical School; CE- BIMED, Faculty of Health Sciences of Fernando Pessoa University (RM), Porto, Portugal ABSTRACT Purpose: Prostate cancer (PCa) is one of the most commonly diagnosed malignancies in the world. Although PSA utili- zation as a serum marker has improved prostate cancer detection it still presents some limitations, mainly regarding its specificity. The expression of this marker, along with the detection of PCA3 mRNA in urine samples, has been suggested as a new approach for PCa detection. The goal of this work was to evaluate the efficacy of the urinary detection of PCA3 mRNA and PSA mRNA without performing the somewhat embarrassing prostate massage. It was also intended to opti- mize and implement a methodological protocol for this kind of sampling. Materials and Methods: Urine samples from 57 patients with suspected prostate disease were collected, without under- going prostate massage. Increased serum PSA levels were confirmed by medical records review.